# Spyre Therapeutics, Inc. (SYRE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SYRE
## Company Profile
- Ticker: SYRE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology, Gastroenterology
## Stock Data
- Close: 104.09 USD
- Market cap: 6005941057.48 USD
- Last updated: 2026-08-12
## Business Overview
### Long-Acting Immunology Antibodies
Spyre Therapeutics develops extended-half-life antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases. Its strategy is to combine established immunology targets with less frequent subcutaneous dosing and, ultimately, multi-mechanism regimens.
### SKYLINE IBD Platform
The Phase 2 SKYLINE platform trial evaluates SPY001, SPY002 and SPY003 as monotherapies and in pairwise combinations in ulcerative colitis. The antibodies target α4β7, TL1A and IL-23, respectively, enabling Spyre to compare individual mechanisms and combination effects within one development framework.
### SPY001
SPY001 is a high-concentration, half-life-extended α4β7 antibody designed for infrequent maintenance dosing. Initial induction data from SKYLINE supported continued development and provided the first clinical proof of concept for Spyre’s platform.
### SKYWAY Rheumatic-Disease Program
The Phase 2 SKYWAY basket trial evaluates the anti-TL1A program SPY072 in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. This trial tests whether the same long-acting immunology approach can extend beyond IBD into multiple rheumatic diseases.
## Why The Stock Is Moving

As of Aug 12, 2026, SYRE closed up 1.31% at $104.09. No new same-company headline was identified in the current news window.

## Future Catalysts

- SKYLINE Part A topline data for SPY002 expected in mid-2026.
- SKYLINE Part A topline data for SPY003 expected in the third quarter of 2026.
- SKYWAY rheumatoid arthritis proof-of-concept results expected in the third quarter of 2026.
- Additional SKYWAY proof-of-concept results expected in the fourth quarter of 2026.
- SKYLINE Part B induction data for monotherapies and combinations expected in 2027.

## Recent News
- 2026-08-10 12:00 EST — [Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa](https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-launch-of-spy772-program-and-initiation-of-phase-2--7a8d5810) — Source: Spyre Therapeutics, Inc.
- 2026-08-07 20:05 EST — [Spyre Therapeutics Announces Grants of Inducement Awards](https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-733c2ae4) — Source: Spyre Therapeutics, Inc.
- 2026-08-04 20:02 EST — [Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SYRE/spyre-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-a2566614) — Source: Spyre Therapeutics, Inc.
- 2026-06-15 12:00 EST — [Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients](https://biopharmsignal.com/news/SYRE/spyre-announces-potential-best-in-class-spy002-anti-tl1a-part-a-induction-result-8bf3759a) — Source: Spyre Therapeutics, Inc.
- 2026-06-03 12:00 EST — [Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA](https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-completion-of-enrollment-in-skyway-basket-trial-eva-ce4b09e5) — Source: Spyre Therapeutics, Inc.